FDA clears Aclaris’ new drug for clinical trial
- Investing.com
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Aclaris Therapeutics Inc (ACRS)
Aclaris Therapeutics Inc stock price live, this page displays NASDAQ ACRS stock exchange data. View the ACRS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Aclaris Therapeutics Inc real time stock price chart below.
What Is the Aclaris Therapeutics Inc Stock Price Today?
The Aclaris Therapeutics Inc stock price today is 1.270.
What Is the Stock Symbol for Aclaris Therapeutics Inc?
The stock ticker symbol for Aclaris Therapeutics Inc is ACRS.
Is ACRS the Same as $ACRS?
$ACRS is a common way to refer to the Aclaris Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Aclaris Therapeutics Inc Trade On?
Aclaris Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Aclaris Therapeutics Inc a Good Stock to Buy?
Determining whether Aclaris Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Aclaris Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ACRS quote. (ISIN: US00461U1051)
What Is the Aclaris Therapeutics Inc Stock Price Today?
The Aclaris Therapeutics Inc stock price today is 1.270.
What Is the Stock Symbol for Aclaris Therapeutics Inc?
The stock ticker symbol for Aclaris Therapeutics Inc is ACRS.
Is ACRS the Same as $ACRS?
$ACRS is a common way to refer to the Aclaris Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Aclaris Therapeutics Inc Trade On?
Aclaris Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Aclaris Therapeutics Inc a Good Stock to Buy?
Determining whether Aclaris Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Aclaris Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ACRS quote. (ISIN: US00461U1051)
NASDAQ
Currency in USD
1.270
+0.080(+6.72%)
Closed·
After Hours
1.2700.000(0.00%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.190
1.330
52 wk Range
0.952
5.170
ACRS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.1901.330
52 wk Range
0.9525.170
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ACRS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
10.200
Upside
+703.15%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Aclaris Therapeutics Inc Company Profile
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Compare ACRS to Peers and Sector
Metrics to compare | ACRS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACRSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.0x | −0.8x | −0.5x | |
PEG Ratio | 0.03 | 0.00 | 0.00 | |
Price / Book | 0.9x | 0.6x | 2.6x | |
Price / LTM Sales | 7.2x | 2.4x | 2.9x | |
Upside (Analyst Target) | - | 148.6% | 57.2% | |
Fair Value Upside | Unlock | 30.3% | 8.9% | Unlock |
Analyst Ratings
5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 10.200
(+703.15% Upside)
Earnings
Latest Release
Feb 27, 2025
EPS / Forecast
-1.01 / -0.29
Revenue / Forecast
9.21M / 2.08M
People Also Watch
FAQ
What Is the Aclaris Therapeutics Inc (ACRS) Stock Price Today?
The Aclaris Therapeutics Inc stock price today is 1.27
What Stock Exchange Does Aclaris Therapeutics Inc Trade On?
Aclaris Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Aclaris Therapeutics Inc?
The stock symbol for Aclaris Therapeutics Inc is "ACRS."
What Is the Aclaris Therapeutics Inc Market Cap?
As of today, Aclaris Therapeutics Inc market cap is 136.52M.
What is Aclaris Therapeutics Inc Earnings Per Share?
The Aclaris Therapeutics Inc EPS is -1.71.
What Is the Next Aclaris Therapeutics Inc Earnings Date?
Aclaris Therapeutics Inc will release its next earnings report on May 13, 2025.
From a Technical Analysis Perspective, Is ACRS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.